BlackRock, Inc. 13D and 13G filings for Corcept Therapeutics Incorporated:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2024-01-22 3:52 pm Purchase | 2023-12-31 | 13G | Corcept Therapeutics Incorporated CORT | BlackRock Inc. BLK | 16,407,696 15.900% | 60,313 (+0.37%) | Filing |
| 2023-01-26 08:52 am Unchanged | 2022-12-31 | 13G | Corcept Therapeutics Incorporated CORT | BlackRock Inc. BLK | 16,347,383 15.200% | 0 (Unchanged) | Filing |
| 2023-01-20 3:00 pm Purchase | 2022-12-31 | 13G | Corcept Therapeutics Incorporated CORT | BlackRock Inc. BLK | 16,347,383 15.200% | 1,299,390 (+8.63%) | Filing |
| 2022-01-28 1:54 pm Sale | 2021-12-31 | 13G | Corcept Therapeutics Incorporated CORT | BlackRock Inc. BLK | 15,047,993 13.000% | -498,531 (-3.21%) | Filing |
| 2021-01-26 2:22 pm Sale | 2020-12-31 | 13G | Corcept Therapeutics Incorporated CORT | BlackRock Inc. BLK | 15,546,524 13.400% | -373,562 (-2.35%) | Filing |